Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Novo's development chief, Martin Holst Lange, has shown optimism about the drug's promise, though he refrained from making ...

JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The ...

If you’re reading this, chances are you’ve heard about CagriSema and are curious whether it’s the right choice for your weight loss journey. Well, let me start by giving you a quick overview.

Investing.com -- Novo Nordisk (CSE: NOVOb) has been placed on JPMorgan’s Catalyst Watch list, signaling heightened anticipation as the company approaches a pivotal moment in its development pipeline.

"Beyond M1Pram and the other projects we are developing, we are very excited to have found a unique solution for the ...

CagriSema combines the GLP-1 receptor agonist semaglutide with cagrilintide, a drug that acts like the blood sugar-controlling hormone amylin. Researchers are testing CagriSema as a treatment for ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs Ozempic and Wegovy. Novo Nordisk, the manufacturer of both, recently ...